Cholesterol rather than Procalcitonin or c-reactive protein predicts mortality in patients with infection

Shock

Volumn 42, Issue 2, 2014, Pages 129-132

  Biller, Katharina ^a   Fae, Peter ^b   Germann, Reinhard ^b   Drexel, Heinz ^c   Walli, Autar K ^d   Fraunberger, Peter ^a  

^a Medical Central Laboratory   (Austria)

^b Clinic of Anesthesiology and Intensive Care Medicine Academic Teaching Hospital   (United States)

^c Vorarlberg Institute for Vascular Investigation and Treatment VIVIT   (Austria)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

C reactive protein; Cholesterol; infection; mortality; procalcitonin; prognosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; PROCALCITONIN; CALCITONIN; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HORMONE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; INFECTION; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT IDENTIFICATION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; SEPSIS; SURVIVOR; BLOOD; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; CHOLESTEROL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PATIENT ADMISSION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; SENSITIVITY AND SPECIFICITY; SEPSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84904673874     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0000000000000187     Document Type: Article

References (21)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 3:1250-1256, 2003.
2. Pierrakos C, Vincent JL: Sepsis biomarkers: a review. Crit Care 14:R15, 2010.
3. Schuetz P, Albrich W, Mueller B: Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med 9:107, 2011.
4. Biller K, Fae P, Germann R, Walli AK, Fraunberger P: How reliable is procalcitonin as antiinflammatory marker? J Lab Med 35:343-348, 2011.
5. Chauffard A, Richet C, Grigaut A: La Cholesterineme au cours de la Tuberculose pulmonaire. Compt Rend Soc Boil ixx:276, 1911.
6. Wendel M, Paul R, Heller AR: Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 16:25-35, 2007.
7. Vermont CL, den Brinker M, Kâkeci N, de Kleijn ED, de Rijke YB, Joosten KF, de Groot R, Hazelzet JA: Serum lipids and disease severity in children with severe meningococcal sepsis. Crit Care Med 33:1610-1615, 2005.
8. Gruber M, Christ-Crain M, Stolz D, Keller U, Müller C, Bingisser R, Tamm M, Mueller B, Schuetz P: Prognostic impact of plasma lipids in patients with lower respiratory tract infectionsVan observational study. Swiss Med Wkly 139: 166-172, 2009.
9. Berbee JF, Havekes LM, Rensen PC: Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 11:97-103, 2005.
10. Netea MG, Joosten LA, Keuter M, Wagener F, Stalenhoef AF, van der Meer JW, Kullberg BJ: Circulating lipoproteins are a crucial component of host defence against invasive Salmonella typhimurium infection. PLoS One 4:e4237, 2009.
11. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 8(4):283-298, 1978.
12. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J, Geneva Sepsis Network. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164:396-402, 2001.
13. Ruiz-Alvarez MJ, García-Valdecasas S, de Pablo R, Sanchez García M, Coca C, Groeneveld TW, Roos A, Daha MR, Arribas I: Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J Intensive Care Med 24:63-71, 2009.
14. Kibe S, Adams K, Barlow G: Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother 66(Suppl 2):ii33-ii40, 2011.
15. Windler E, Ewers-Grabow U, Thiery J, Walli A, Seidel D, Greten H: The prognostic value of hypocholesterolemia in hospitalized patients. Clin Investig 72:939-943, 1994.
16. Chiarla C, Giovannini I, Giuliante F, Zadak Z, Vellone M, Ardito F, Clemente G, Murazio M, Nuzzo G: Severe hypocholesterolemia in surgical patients, sepsis, and critical illness. J Crit Care 25:361, 2010.
17. Jasicska M, Owczarek J, Orszulak-Michalak D: Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 59:483, 2007.
18. Fraunberger P, Gröne E, Gröne HJ, Walli AK: Simvastatin reduces endotoxininduced nuclear factor kappaB activation and mortality in guinea pigs despite lowering circulating low-density lipoprotein cholesterol. Shock 32:159, 2009.
19. Zhang S, Luo L, Wang Y, Rahman M, Lepsenyi M, Syk I, Jeppsson B, Thorlacius H: Simvastatin protects against T cell immune dysfunction in abdominal sepsis. Shock 38:524-531, 2012
20. Azevedo LC, Park M, Schettino GP: Novel potential therapies for septic shock. Shock 30(Suppl 1):60-66, 2008.
21. Piechota M, Barylski M, Hannam S, Piechota-Urbacska M, Banach M: Rationale of statin therapy in septic patients. Curr Vasc Pharmacol 11:795, 2013.